{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:25:17Z","timestamp":1760955917360,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jjcc.2018.12.013","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T11:26:08Z","timestamp":1549365968000},"page":"507-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance"],"prefix":"10.1016","volume":"73","author":[{"given":"Hiroshi","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Atarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Koretsune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Fukaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2018.12.013_bib0190","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0195","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1253\/circj.CJ-11-0191","article-title":"Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation - sub-analysis in Japanese population in RE-LY trial","volume":"75","author":"Hori","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0200","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0205","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0210","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.amjmed.2014.01.031","article-title":"Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation","volume":"127","author":"Larsen","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0215","doi-asserted-by":"crossref","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0220","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/STROKEAHA.115.011476","article-title":"Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation","volume":"47","author":"Chan","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0225","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","article-title":"Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation","volume":"68","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0230","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jjcc.2016.05.011","article-title":"Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency","volume":"69","author":"Fukaya","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0235","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.joa.2013.04.010","article-title":"Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation","volume":"30","author":"Miyamoto","year":"2014","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0240","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1080\/03007995.2017.1374935","article-title":"Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data","volume":"33","author":"Kohsaka","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jjcc.2018.09.003","article-title":"Contemporary trend of reduced-dose non-vitamin K antagonists in Japanese patients with atrial fibrillation: a cross-sectional analysis of a multicenter outpatient registry","volume":"73","author":"Ono","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0250","unstructured":"Prazaxa (dabigatran etexilate capsules) (Japanese package insert)]. [http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/650168_3339001M1024_1_12.pdf] (accessed June 1, 2018)."},{"key":"10.1016\/j.jjcc.2018.12.013_bib0255","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1253\/circj.CJ-10-1119","article-title":"Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry","volume":"75","author":"Atarashi","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0260","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1253\/circj.CJ-14-0344","article-title":"Inappropriate use of oral anticoagulants for patients with atrial fibrillation: 1-year outcomes of the Fushimi AF Registry","volume":"78","author":"Akao","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0265","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.joa.2015.11.008","article-title":"Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: preliminary report of the J-Dabigatran Surveillance","volume":"32","author":"Inoue","year":"2016","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0270","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0275","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0280","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0285","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1253\/circj.CJ-16-0066","article-title":"Beneficial effect of non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation: results of the J-RHYTHM Registry 2","volume":"80","author":"Kodani","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0290","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1253\/circj.CJ-16-1337","article-title":"Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients: Fushimi AF Registry","volume":"81","author":"Yamashita","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0295","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.joa.2016.11.003","article-title":"Current use of direct oral anticoagulants for atrial fibrillation in Japan: findings from the SAKURA AF Registry","volume":"33","author":"Okumura","year":"2017","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0300","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/CIRCULATIONAHA.115.015710","article-title":"Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study","volume":"132","author":"Maura","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0305","doi-asserted-by":"crossref","first-page":"e002758","DOI":"10.1136\/bmjopen-2013-002758","article-title":"Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study","volume":"3","author":"Sorensen","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0310","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/joim.12683","article-title":"Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study","volume":"283","author":"Staerk","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0315","doi-asserted-by":"crossref","first-page":"e008150","DOI":"10.1161\/JAHA.117.008150","article-title":"Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation","volume":"7","author":"Chan","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0320","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1160\/TH17-10-0733","article-title":"Effectiveness and safety of non-vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation","volume":"118","author":"Hohnloser","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0325","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijcard.2018.03.063","article-title":"The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation","volume":"261","author":"Lee","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0330","doi-asserted-by":"crossref","first-page":"e007633","DOI":"10.1161\/JAHA.117.007633","article-title":"Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)","volume":"7","author":"Steinberg","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0335","doi-asserted-by":"crossref","first-page":"e0191722","DOI":"10.1371\/journal.pone.0191722","article-title":"Apixaban 5 and 2.5mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approach","volume":"13","author":"Li","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0340","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/joim.12702","article-title":"Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial","volume":"283","author":"Proietti","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0345","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jjcc.2013.03.010","article-title":"Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice","volume":"62","author":"Kawabata","year":"2013","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0355","doi-asserted-by":"crossref","first-page":"e004075","DOI":"10.1161\/JAHA.116.004075","article-title":"Impact of blood pressure control on thromboembolism and major hemorrhage in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry","volume":"5","author":"Kodani","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0360","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.amjcard.2013.11.057","article-title":"Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation","volume":"113","author":"Inoue","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0365","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1253\/circj.CJ-14-1245","article-title":"Low body weight is associated with the incidence of stroke in atrial fibrillation patients\u2013insight from the Fushimi AF Registry","volume":"79","author":"Hamatani","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.12.013_bib0370","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","article-title":"Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial","volume":"65","author":"B\u00f6hm","year":"2015","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508718303666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508718303666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:00:51Z","timestamp":1760274051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508718303666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0914508718303666"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2018.12.013","relation":{},"ISSN":["0914-5087"],"issn-type":[{"type":"print","value":"0914-5087"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2018.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.","name":"copyright","label":"Copyright"}]}}